Key result
Hypertension in severe COVID-19 is linked to distinct plasma metabolomic and proteomic alterations.
Why the study?
What plasma biomarkers are associated with unfavorable COVID-19 progression in hypertensive compared to non-hypertensive patients?
Observational (n=63)
What plasma biomarkers are associated with unfavorable COVID-19 progression in hypertensive compared to non-hypertensive patients?
Answers are grounded in this paper and cite their sources.
Plasma myo-inositol, gelsolin, and PC 32:1 are key biomarkers distinguishing hypertensive from non-hypertensive patients with severe COVID-19, highlighting altered stress response and lipid metabolism.
Hypertension is one of the most common risk factors for COVID-19 clinical progression. The identification of plasma biomarkers for anticipating worse clinical outcomes and to better understand the shared mechanisms between hypertension and COVID-19 are needed. A hypothesis-generating study was designed to compare plasma proteomics and metabolomics between 22 hypertensives (HT) and 41 non-hypertensives (nHT) patients with the most unfavorable COVID-19 progression. A total of 43 molecules were significantly differed between HT (n = 22) and nHT (n = 41). Random Forest (RF) analysis identified myo-inositol, gelsolin and phosphatidylcholine (PC) 32:1 as the top molecules for distinguishing between HT and nHT. Plasma myo-inositol and gelsolin were higher (P = 0.03 and P = 0.02, respectively) and plasma PC 32:1 was lower (P = 0.03) in HT compared to nHT. Biological processes like stress response and blood coagulation, along with KEGG pathways including ascorbate and aldarate metabolism (P = 0.021) and linoleic acid metabolism (P = 0.028), were altered in hypertensive patients with the most unfavorable COVID-19 progression. There is a clear link between hypertension and severe COVID-19. Key biological pathways to consider for improving the prognosis and quality of life of hypertensive patients who become infected with SARS-CoV-2 include oxidative stress, ascorbate and aldarate metabolism, lipid metabolism, immune system and inflammation.
No takes yet. Share an insight, caveat, or question.
Sánchez et al. (2025) conducted an observational in COVID-19 (n=63). Hypertension vs. Non-hypertension was evaluated on Plasma proteomics and metabolomics differences. Hypertension in patients with unfavorable COVID-19 progression was associated with higher plasma myo-inositol and gelsolin, and lower phosphatidylcholine 32:1.
Synapse has enriched 10 related papers. Consider them for comparative context: